X4 Pharmaceuticals (XFOR) Profit After Tax (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Profit After Tax of -$23.9 million for Q4 2025, up 19.84% on a QoQ basis from -$29.8 million in Q3 2025, and up 39.98% year-over-year from -$17.1 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Profit After Tax (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Profit After Tax history runs 9 years deep, the most recent figure standing at -$23.9 million for Q4 2025.
- Quarterly Profit After Tax rose 39.98% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 111.41% YoY) and the FY2025 annual result came in at -$79.2 million, down 111.48% from the prior year.
- Profit After Tax was -$23.9 million for Q4 2025 at X4 Pharmaceuticals, up from -$29.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
- A 5-year average of -$20.0 million and a median of -$22.9 million in 2022 frame the typical range for Profit After Tax.
- Peak annual rise in Profit After Tax reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
- X4 Pharmaceuticals' Profit After Tax stood at -$30.2 million in 2021, then increased by 3.65% to -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then tumbled by 108.16% to -$39.8 million in 2024, then soared by 39.98% to -$23.9 million in 2025.
- Business Quant data shows XFOR's Profit After Tax at -$23.9 million in Q4 2025, -$29.8 million in Q3 2025, and -$25.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | X4 Pharmaceuticals | 163.88 Mn | -53.16 Mn | 2.20 Mn | -23.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.90 Mn |
| Sep 30, 2025 | -29.82 Mn |
| Jun 30, 2025 | -25.74 Mn |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | -39.82 Mn |
| Sep 30, 2024 | -36.70 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.77 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -30.21 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |
| Mar 31, 2021 | -18.68 Mn |